SOURCE: IO News Wire

IO News Wire

December 13, 2010 07:30 ET

(AMEX: CRMD) The Undervalued Biotech

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - December 13, 2010) - CorMedix, Inc. (NYSE Amex: CRMD) was covered by OutsideIn Research on December 3rd, 2010 in an article outlining the hidden values of the company.

CorMedix currently has two products in Phase 2 clinical development. Combined, these two products represent an estimated $1.1 billion sales opportunity for CorMedix.

Neutrolin could potentially become the first FDA-approved catheter lock solution used in the prevention of Catheter-Related Bloodstream Infection (CRBI). There are approximately 80,000 patients using a catheter, this represents an estimated $675 million in sales.

Deferiprone (CRMD001) aims at preventing Contrast Induced Nephropathy (CIN) commonly found in patients with chronic kidney disease. This market represents an estimated $365 million in potential sales.

These two products in development along with a large cash balance and relative low stock price put CorMedix in a very good position to meet the Griffin Securities target price estimate of $6.00.

To view the full article

Other active stocks are Marina Biotech (NASDAQ: MRNA) Pfizer Inc. (NYSE: PFE) and Eli Lilly & Co (NYSE: LLY)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information